GLP-1s and the gallbladder: gallstones, and taking one without a gallbladder
Reviewed 23 sourcesPublished by PepVault
Gallstones on Ozempic, Wegovy, Mounjaro and Zepbound: each label's rate against placebo, when they show up, and what is known if your gallbladder is out.

- Last reviewed
- Sources
- 23
- Questions
- 9
- Compounds
- 3
The short answer
Gallstones are a real but uncommon GLP-1 side effect. On the US labels, 1.6% of adults on Wegovy reported them against 0.7% on placebo, and 1.1% on Zepbound against 1%; gallbladder inflammation came to 0.6% to 0.7% against 0.2%. Reports put the typical start months in. No label addresses taking one after gallbladder removal, and none rules it out: that call is your prescriber's.
- Adults on Wegovy: gallstones 1.6% against 0.7% on placebo; on Zepbound 1.1% against 1%.
- Across 76 trials a GLP-1 raised gallbladder and bile-duct problems by 37%, most at higher doses, in longer trials and in weight-loss trials.
- Reported cases started a median of 182 days in, so this is a months-in effect, unlike the early nausea.
- No label addresses taking a GLP-1 without a gallbladder, and none rules it out; the decision is the prescriber's.
Evidence: Strong for the rates: the four FDA labels, built on randomized placebo-controlled trials, and a 76-trial meta-analysis. Thin for life without a gallbladder: no label or trial addresses it, and the human data are one trial subgroup and one case report.

How common are gallstones on Ozempic, Wegovy, Mounjaro and Zepbound?
Uncommon on all four: each label puts gallstones at 0.4% to 3.8% of the people in its trials. The gallbladder is a small pouch under the liver that stores bile, the fluid that helps digest fat. Gallstones (cholelithiasis) are hard lumps that form in it; cholecystitis means the gallbladder itself is inflamed. Ozempic and Wegovy are semaglutide, Mounjaro and Zepbound tirzepatide. Each US label's rates against placebo1234:
| Label and group | Trials behind the number | Gallstones: drug vs placebo | Gallbladder inflammation: drug vs placebo |
|---|---|---|---|
| Ozempic 0.5 mg | Placebo-controlled type 2 diabetes trials | 1.5% vs 0% | Not given |
| Ozempic 1 mg | The same trials | 0.4% vs 0% | Not given |
| Mounjaro 5 to 15 mg | 2 type 2 diabetes trials | 0.6% vs 0% (also counts biliary colic and removal) | Not given |
| Wegovy 2.4 mg shot, adults | Weight-loss trials | 1.6% vs 0.7% | 0.6% vs 0.2% |
| Wegovy 25 mg tablet, adults | 1 weight-loss trial | 2.5% vs 1% | Not given |
| Wegovy shot, ages 12 and up | 1 weight-loss trial | 3.8% vs 0% | 0.8% vs 0% |
| Zepbound 5 to 15 mg | 2 weight-loss trials | 1.1% vs 1% | 0.7% vs 0.2% |
The extra over placebo is small in adults: under one percentage point for gallstones on the Wegovy shot, and close to level on Zepbound, though Zepbound's label also counts gallbladder removal (cholecystectomy) in 0.2% against none on placebo4. Teenagers on Wegovy had the highest rates of any group, and the label says so plainly2. The labels warn that rates from different trials cannot be compared directly13.

How much does a GLP-1 raise the risk of gallbladder problems?
By about a third across the class, and about double in semaglutide's weight-loss trials. A meta-analysis (a study that pools many trials) of 76 randomized trials and 103,371 people found gallbladder and bile-duct problems 1.37 times as often on a GLP-1 as on placebo or another treatment, that is, 37% more often. The rise was larger in weight-loss trials (2.29 times) than in diabetes trials (1.27 times), at higher doses (1.56 times) than lower ones (0.99, no rise), and in longer trials than shorter ones5.
In absolute numbers it stays small. Across four placebo-controlled STEP trials of semaglutide 2.4 mg (3,683 people), gallbladder events came to 1.92 per 100 person-years on the drug against 0.82 on placebo; person-years means people times years followed. The authors put it at about one extra gallbladder event for every 90 to 100 people treated for a year6. In SELECT, the heart trial of semaglutide 2.4 mg in 17,604 people with heart disease, gallbladder problems were reported by 2.8% against 2.3% on placebo, mostly gallstones (1.4% against 1.1%); inflammation was level at 0.6% in both groups7. For tirzepatide, a pooled analysis of nine trials found gallbladder and bile-duct problems combined about twice as often as on placebo or basal insulin (relative risk 1.97), with no single diagnosis significant on its own8.
Does a higher dose mean more gallbladder trouble?
For tirzepatide, the trial registries point that way. ClinicalTrials.gov lists every serious adverse event by arm, and serious gallstone events rose with the dose in SURMOUNT-191011:
| Trial and group | People | Serious gallstone events | Share (our division) |
|---|---|---|---|
| STEP 1, semaglutide 2.4 mg (75 weeks) | 1,306 | 12 | 0.9% |
| STEP 1, placebo | 655 | 1 | 0.2% |
| SURMOUNT-1, tirzepatide 5 mg (up to 193 weeks) | 630 | 3 | 0.5% |
| SURMOUNT-1, tirzepatide 10 mg | 636 | 6 | 0.9% |
| SURMOUNT-1, tirzepatide 15 mg | 630 | 7 | 1.1% |
| SURMOUNT-1, placebo | 643 | 3 | 0.5% |
| SURMOUNT-5, tirzepatide 15 mg or highest tolerated (72 weeks) | 374 | 2 | 0.5% |
| SURMOUNT-5, semaglutide 2.4 mg or highest tolerated | 376 | 3 | 0.8% |
The counts are small: read them as a direction, not a verdict. STEP 1 also listed serious gallbladder inflammation for 7 people on semaglutide against none on placebo9. A large health-records study of people with obesity and type 2 diabetes found slightly more gallstones on semaglutide than on tirzepatide in the first year (hazard ratio 1.11)12.
When do gallbladder problems start on a GLP-1?
Months in, not days. None of the four labels gives a week. The best timing data come from the FDA's adverse event reports: across reports from 2004 to mid-2024 naming a GLP-1 as the main suspect in gallstones or gallbladder inflammation (1,651 people), the median start was 182 days after the first dose, about six months. Tirzepatide's median was the shortest at 80 days and exenatide's the longest at 23013. These are voluntary reports, not a trial. Our reading: tirzepatide came to market last, so its reports cover the shortest stretch of use.
The trials agree: the risk rose in longer trials5, and in LEADER, which ran liraglutide for 3.5 to 5 years, 141 of 4,668 people had an acute gallbladder or bile-duct event against 88 of 4,672 on placebo14. That timing sets gallbladder trouble apart from nausea, which mostly comes during the dose climb (pepvault.app/guides/ozempic-and-wegovy-side-effects).
PepVault's weight log charts every weigh-in you enter, so you and your prescriber can see how fast the weight is coming off week by week. Track your weight in PepVault
Why do GLP-1s cause gallstones?
Two routes, both measured in people. First, the drug slows the gallbladder. After a meal the gut releases a hormone called cholecystokinin, the signal that squeezes the gallbladder; a GLP-1 infusion suppressed that rise in 10 healthy people and 10 people with type 1 diabetes15. In healthy volunteers given a cholecystokinin drip, a single exenatide shot cut how much of its bile the gallbladder emptied, 28.8% against 46.1% on placebo16. After 12 weeks on liraglutide 3.0 mg the gallbladder still emptied as fully, but took about twice as long to get there, 151 minutes against 7717. The pooled STEP authors call the result bile stasis: bile standing still in the gallbladder, where stones can form6.
Second, losing weight fast changes bile itself: rapid weight loss is a major risk factor for cholesterol gallstones, which is why they are common after bariatric surgery18. The Wegovy label says both parts: rapid weight loss can raise the risk, yet gallbladder disease was still more common on Wegovy than on placebo after accounting for the weight lost2. Zepbound's label ties its gallbladder events to weight reduction4.
What are the signs of a gallbladder problem on a GLP-1?
All four patient guides give the same list: pain in the upper stomach, yellowing of the skin or the whites of the eyes (jaundice), fever, and clay-colored stools1234. The Wegovy guide adds that some gallbladder problems need surgery2.
Commonly reported: in the open write-ups of 41 people who took semaglutide that our reports page counted (2019 to 2026), 2 named gallbladder pain; none of 77 people's tirzepatide write-ups did19.
- Write down when the pain started, where it sits, how long it lasts and what you had eaten.
- Check yourself for the label's other three signs: yellow skin or eyes, a fever, pale clay-colored stools.
- Note your current dose and the date of your last step-up.
- If gallbladder surgery is planned, tell the surgeon and the anesthesia team you take a GLP-1: all four labels ask for that, because a slow stomach can matter under anesthesia1234.
PepVault's side-effect log keeps each symptom in your own words, with its severity from minimal to very severe, the date and a note, and the doctor's report lists what you logged. Log it in PepVault
When to get help The labels ask you to tell your healthcare provider right away if you get upper stomach pain, yellow skin or eyes, a fever or clay-colored stools on the drug134.
Can you take a GLP-1 without a gallbladder?
No label addresses it. None of the four lists gallbladder removal as a reason not to take the drug, and none gives advice for people who have had it; removal appears only as an outcome, counted in Mounjaro's 0.6% and Zepbound's 0.2%34. The decision is your prescriber's, and here is what is known.
- What changes in the body (our reading). Without a gallbladder, bile flows from the liver through the bile ducts straight into the small intestine instead of being stored20. The two events the labels count most, stones in the gallbladder and its inflammation, need a gallbladder to happen. The bile ducts remain, and bile-duct disease rose on a GLP-1 too in the 76-trial analysis5.
- What the trials show. On ClinicalTrials.gov, STEP 1 and SURMOUNT-1 list no gallbladder history among their exclusions, but neither reports results for people without a gallbladder910. The closest data is SELECT: 13.6% of its people had a history of gallbladder disease (the paper does not say how many had it removed), and in that group gallbladder problems came to 3.1% on semaglutide against 2.9% on placebo, about level7.
- One documented case. A 72-year-old man whose inflamed gallbladder was removed while on dulaglutide stayed on it after surgery, with no new bile-duct trouble over 8 months21.
- What still applies. Every other warning stays the same, including pancreatitis, the inflamed pancreas all four labels warn about1234.
Does a GLP-1 cause more diarrhea if you have no gallbladder?
No trial has measured it. Removal itself changes stools in some people: softer, more frequent stools in a small number, usually temporary20. When watery diarrhea lasts after removal, it is often bile acid diarrhea: across 361 such patients, 70% tested positive for it22.
The surprise runs the other way: in a 6-week trial of 52 people with primary bile acid diarrhea (the kind with no surgery behind it), daily liraglutide cut stool frequency by a quarter or more in 77% of people, against 50% on colesevelam, the standard treatment23. Nobody has tested it after gallbladder removal.
Can gallstones on a GLP-1 be prevented?
No trial has tested prevention in GLP-1 users. The candidate comes from weight-loss surgery: in the UPGRADE trial of 985 people, ursodeoxycholic acid (a bile acid tablet) for 6 months after surgery was followed by symptomatic gallstones in 6.5% against 9.7% on placebo, a difference that fell short of significance overall; it helped clearly in people who had no stones before a gastric bypass18. The authors of the pooled STEP analysis write that whether it would help people starting a GLP-1 is unknown6. Whether anyone takes it is a prescriber's decision (after a sleeve or bypass: pepvault.app/guides/glp-1-after-bariatric-surgery).
Sources
- OZEMPIC (semaglutide) injection, prescribing information and Medication Guide. Novo Nordisk. DailyMed, version 20, published June 10, 2026. dailymed.nlm.nih.gov
- WEGOVY (semaglutide) injection and tablets, prescribing information and Medication Guide. Novo Nordisk. DailyMed, version 19, published June 30, 2026. dailymed.nlm.nih.gov
- MOUNJARO (tirzepatide) injection, prescribing information and Medication Guide. Eli Lilly. DailyMed, version 40, published September 2, 2026. dailymed.nlm.nih.gov
- ZEPBOUND (tirzepatide) injection, prescribing information and Medication Guide. Eli Lilly. DailyMed, version 40, published September 2, 2026. dailymed.nlm.nih.gov
- He L et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2022. PubMed 35344001
- Ukkonen M et al. Gallbladder-related adverse events with semaglutide 2.4 mg: pooled analysis of placebo-controlled STEP trials. Diabetes Obes Metab. 2026. PubMed 42410302
- Kushner RF et al. Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial. Obesity (Silver Spring). 2025. PubMed 39948761
- Zeng Q et al. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Front Endocrinol. 2023. PubMed 37908750
- STEP 1 (NCT03548935), Novo Nordisk: results, serious adverse events, weeks 0 to 75. ClinicalTrials.gov, read November 20, 2026. clinicaltrials.gov
- SURMOUNT-1 (NCT04184622), Eli Lilly: results, serious adverse events, baseline up to week 193. ClinicalTrials.gov, read November 20, 2026. clinicaltrials.gov
- SURMOUNT-5 (NCT05822830), Eli Lilly: results, serious adverse events, baseline up to 72 weeks. ClinicalTrials.gov, read November 20, 2026. clinicaltrials.gov
- Ghusn W et al. Biliary and pancreatic safety of incretin-based therapies in obesity and type 2 diabetes: a propensity-matched real-world comparison of tirzepatide, semaglutide, and DPP-4 inhibitors. J Clin Med. 2026. PubMed 42941539
- Tao C et al. Glucagon-like peptide-1 receptor agonist-induced cholecystitis and cholelithiasis: a real-world pharmacovigilance analysis using the FAERS database. Front Pharmacol. 2025. PubMed 40697657
- Nauck MA et al. Effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the LEADER randomized trial. Diabetes Care. 2019. PubMed 31399438
- Rehfeld JF et al. Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs. Scand J Gastroenterol. 2018. PubMed 30449207
- Keller J et al. Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects. Regul Pept. 2012. PubMed 22960288
- Nexøe-Larsen CC et al. Effects of liraglutide on gallbladder emptying: a randomized, placebo-controlled trial in adults with overweight or obesity. Diabetes Obes Metab. 2018. PubMed 29892986
- Haal S et al. Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery (UPGRADE): a multicentre, double-blind, randomised, placebo-controlled superiority trial. Lancet Gastroenterol Hepatol. 2021. PubMed 34715031
- PepVault. Semaglutide and tirzepatide: what people report (41 and 77 people's open write-ups, counted November 19, 2026). pepvault.app
- National Institute of Diabetes and Digestive and Kidney Diseases. Treatment for gallstones. Last reviewed November 2017. niddk.nih.gov
- Butler J et al. Possible dulaglutide-associated cholecystitis with safe continuation post cholecystectomy. Am J Health Syst Pharm. 2021. PubMed 33594405
- Ruiz-Campos L et al. Systematic review with meta-analysis: the prevalence of bile acid malabsorption and response to colestyramine in patients with chronic watery diarrhoea and previous cholecystectomy. Aliment Pharmacol Ther. 2019. PubMed 30585336
- Kårhus ML et al. Safety and efficacy of liraglutide versus colesevelam for the treatment of bile acid diarrhoea: a randomised, double-blind, active-comparator, non-inferiority clinical trial. Lancet Gastroenterol Hepatol. 2022. PubMed 35868334
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.